On 10 December 2025, Amplex AB (“Amplex” or the “Bidder”) announced a public offer to the shareholders and warrant holders of ADDvise Group AB (publ) (“ADDvise” or the “Company”) to transfer all shares and warrants in the Company to Amplex (the “Offer”). Today, Amplex announced an increase of the price in the Offer to SEK 1.72 in cash for each class A and class B share and SEK 0.52 in cash for each warrant of series TO1A and series TO1B (the “Revised Offer”).

Amplex has also entered into agreements on conditional acquisitions of shares and warrants with Per Åhlgren, Rikard Akhtarzand, Thomas Eklund, Åsa Riisberg and Magnus Vahlquist, who in aggregate control approximately 21.11 per cent of the share capital and approximately 16.55 per cent of the votes in ADDvise. Fredrik Celsing’s undertaking that was entered into in connection with the announcement of the Offer on 10 December 2025 continues to apply to the Revised Offer. This means that shareholders who in aggregate control approximately 21.70 per cent of the share capital and approximately 16.99 per cent of the votes in ADDvise, have undertaken to sell their shares to Amplex or to accept the Revised Offer. In total, the shares covered by the conditional acquisitions and the previous undertaking and the shares owned or controlled by Amplex represent approximately 51.49 per cent of the share capital and approximately 60.57 per cent of the votes in ADDvise.

Rikard Akhtarzand’s and Thomas Eklund’s agreements on conditional sales as well as Fredrik Celsing’s acceptance undertaking and position as CEO of Amplex means that they have conflicts of interest pursuant to Rule II.18 of the Takeover rules for certain trading platforms issued by the Stock Market Self-Regulation Committee (the “Takeover Rules”). Fredrik Celsing has not participated, and neither of Fredrik Celsing, Rikard Akhtarzand or Thomas Eklund will going forward participate, in the Company’s handling or decisions regarding the Revised Offer.

Against this background, ADDvise has formed an independent bid committee consisting of the board members Anna Ljung and Johanne Brændgaard. The independent bid committee will evaluate the Revised Offer as well as obtain and publish a fairness opinion regarding the shares and warrants in ADDvise in accordance with Rule IV.3 of the Takeover Rules

Further information about the Revised Offer is available on Amplex’ website, https://life-science-offer.com/.

For further information, please contact:

Anna Ljung, board member
Tel: +46 (0) 707 66 60 30, Email: anna@ljung.biz

About ADDvise Group

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.7 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.

Attachments
Amplex has increased the consideration in the public offer to the shareholders and warrant holders of ADDVise

Läs mer på MFN